argenex (NASDAQ:ARGX) Stock Keeps “Neutral” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their neutral rating on shares of argenex (NASDAQ:ARGX) in a research note issued to investors on Friday morning.

ARGX has been the topic of several other reports. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. Royal Bank Of Canada increased their target price on argenex from $1,025.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Weiss Ratings cut argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 23rd. Morgan Stanley raised their target price on shares of argenex from $1,230.00 to $1,250.00 and gave the stock an “overweight” rating in a report on Monday, August 31st. Finally, Robert W. Baird cut their price target on shares of argenex from $932.00 to $823.00 and set a “neutral” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,158.32.

argenex Price Performance

Shares of NASDAQ ARGX traded down $7.14 during midday trading on Friday, reaching $817.89. 111,911 shares of the stock were exchanged, compared to its average volume of 345,039. The business has a 50-day simple moving average of $959.93 and a two-hundred day simple moving average of $877.49. The company has a market capitalization of $51.17 billion, a price-to-earnings ratio of 31.41, a P/E/G ratio of 0.86 and a beta of 0.44. argenex has a 12 month low of $661.85 and a 12 month high of $1,072.75.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 43.59%. The company had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. Equities research analysts expect that argenex will post 28.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its stake in shares of argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares in the last quarter. Sands Capital Management LLC raised its position in argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares in the last quarter. Jennison Associates LLC lifted its stake in argenex by 3.4% in the first quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after acquiring an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in argenex by 1.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after acquiring an additional 2,579 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in argenex by 98.9% in the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after acquiring an additional 53,293 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Company Profile

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).